Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 988 across all filing types
Latest filing 2025-04-27 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Telix Provides Regulatory Update on TLX101-CDx 3 pages 153.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited providing a regulatory update on their New Drug Application (NDA) for TLX101-CDx. It discusses the receipt of a Complete Response Letter (CRL) from the FDA, which is a regulatory communication about the status of a drug approval application. The document includes details about the FDA's decision, the company's response plans, and an investor conference call announcement. There are no financial statements, detailed financial performance data, or comprehensive management discussion of financial results. The document is primarily a regulatory update and investor communication about a specific regulatory event, not a full financial report or earnings release. It is also not a report publication announcement since it contains substantive information rather than just announcing a report's availability. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-04-27 English
Pending Release of Shares from Voluntary Escrow 2 pages 149.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the pending release of shares from voluntary escrow related to an acquisition. It references compliance with ASX Listing Rule 3.10A and details the number of shares and escrow release date. The content is focused on share release information and does not contain financial statements, management discussion, or detailed financial data. It is not a full report but an announcement about share release. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-04-23 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-04-22 English
Pending Release of Shares from Voluntary Escrow 2 pages 147.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Pending Release of Shares from Voluntary Escrow' by Telix Pharmaceuticals Limited. It discusses the release of ordinary shares from voluntary escrow related to a previous acquisition. The content is a regulatory announcement about share release and escrow conditions, not a financial report or detailed analysis. It references compliance with ASX Listing Rule 3.10A and provides background on the company and contact information. There are no financial statements, earnings data, or management discussion. The document is relatively short (6165 characters) and serves as a formal notification to the market about share escrow release. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-04-21 English
Telix Reports US$186M Q1 Revenue, Up 62% YOY 5 pages 243.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 22 April 2025 providing a detailed update on Telix Pharmaceuticals Limited's commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). It includes unaudited revenue figures, quarter-over-quarter and year-over-year growth, FY 2025 guidance reaffirmation, business segment updates, clinical trial progress, regulatory approvals, manufacturing updates, and board changes. The document is approximately 15,000 characters long and contains substantive financial data and operational commentary for the quarter, not just a brief summary or a notice of report publication. It is not a full annual report (10-K or 20-F), but a comprehensive quarterly update with financial results and business outlook. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-04-21 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-04-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.